Venous Thromboembolism Market and Forecast Analysis to 2026: The VTE NOAC market will grow briefly, but begin to erode in 2024 with the introduction of generics - ResearchAndMarkets.com

DUBLIN--()--The "Venous Thromboembolism Market and Forecast Analysis to 2026" drug pipelines has been added to ResearchAndMarkets.com's offering.

Disease Overview

Venous thromboembolism (VTE) consists of deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT refers to the formation of thrombi or blood clots in deep veins, which can block blood flow. A PE can form if the clot or a fragment travels to the lung, blocking oxygenated blood flow. VTE is estimated to be the third most common cardiovascular disease, and represents a significant financial burden for healthcare systems. PE is estimated to be the leading cause of in-hospital mortality, accounting for approximately 10% of deaths in this setting.

Market Snapshot

  • The VTE NOAC market will grow briefly, but begin to erode in 2024 with the introduction of generics.
  • Survey of 222 specialists in the US, Japan, and five major EU markets sheds light on prescribing trends in VTE.
  • Development of antidotes in the NOAC drug class will likely increase their adoption over traditional warfarin treatment.
  • Improving NOACs pipeline agents will reduce risk of major bleeding and provide consistent anticoagulation.
  • EU payers limit use due to high cost, while US payers support uptake.

Key Topics Covered:

Forecast: Venous Thromboembolism

Market Dynamics

Forecast And Future Trends

Market Definition And Methodology

Primary Research Methodology

Bibliography

Product Profile: Eliquis

Product Profile: Pradaxa

Product Profile: Savaysa

Product Profile: Xarelto

Treatment: Venous Thromboembolism

Disease Definition And Diagnosis

Current Treatment Options

Prescribing Trends

Epidemiology: Venous Thromboembolism

Disease Background

Methodology

Forecast: Deep Vein Thrombosis

Forecast: Pulmonary Embolism

Epidemiologist Insight

Strengths And Limitations

Bibliography

Appendix: Additional Sources

Marketed Drugs: Venous Thromboembolism

Product Overview

Product Profile: Bevyxxa

Product Profile: Eliquis

Product Profile: Pradaxa

Product Profile: Savaysa

Product Profile: Xarelto

Noacs Pricing, Reimbursement, And Access

Executive Summary

Regulatory Labels

Global Payer And Key Opinion Leader Insights

Us Pricing

Us Reimbursement

Japan

Pricing In The Five Major Eu Markets

Pipeline: Venous Thromboembolism

Executive Summary

Pipeline Trends

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/lk234b/venous?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiovascular Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiovascular Drugs